U.S. urges 15-year sentence for ex-Theranos president Balwani
Reuters
Published Dec 01, 2022 11:53AM ET
Updated Dec 01, 2022 06:06PM ET
By Jonathan Stempel
(Reuters) - U.S. prosecutors have asked a judge to sentence former Theranos Inc President Ramesh "Sunny" Balwani to 15 years in prison for defrauding investors and patients in the blood-testing startup once led by Elizabeth Holmes.
Balwani countered that probation, meaning no prison time, is sufficient, citing his own investment losses in a company once valued at $9 billion, and saying he never sought the "fame or media attention" that Holmes attracted as Theranos' public face.
The recommendations were filed on Wednesday night in the federal court in San Jose, California, where Balwani will be sentenced on Dec. 7 by U.S. District Judge Edward Davila.
On Nov. 18, the judge sentenced Holmes to 11-1/4 years in prison, calling Theranos a once-exciting venture "dashed by untruths, misrepresentations, plain hubris and lies."
She was convicted in January on four counts of fraud and conspiracy but acquitted of defrauding patients, while Balwani was convicted in January on all 12 fraud and conspiracy counts he faced.
Prosecutors also want a court order requiring Balwani to pay $803.8 million, which they acknowledge he does not have, to cover losses by investors including Walgreens, Safeway and the late U.S. Secretary of State George Shultz.
Holmes and Balwani were convicted of lying about Theranos' technology, which once offered hope that an array of medical diagnostic tests could be performed with just a few drops of blood.
Prosecutors said Balwani deserved a longer sentence than Holmes because his offenses, particularly the conspiracy to defraud patients with inaccurate blood tests, showed a "conscious or reckless risk of death or serious bodily injury."
Defense lawyers said there is no likelihood Balwani will commit another crime, and that he played a "demonstrably" lesser role than Holmes in the conduct underlying his conviction.
The case is U.S. v. Balwani, U.S. District Court, Northern District of California, No. 18-cr-00258.
Get The News You Want
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.